title: Surgical choroidal neovascular membrane removal in the era of anti-vascular endothelial growth factor agents.
abstract: Intravitreal anti-vascular endothelial growth factor (VEGF) agents have obtained acceptance as the mainstay in the management strategy of subfoveal choroidal neovascular membranes (CNVM) due to varying etiologies. Few drawbacks include need for repeated intravitreal injections, with its adjunct risks, and the lack of a predefined treatment end point, which can cause doubts and uncertainty in the mind of the patient. Furthermore, it remains a significant financial burden for the patient. Herein we report our data of three patients who were reluctant for further re-injections of anti-VEGF agents and were therefore offered surgical removal of the CNVM by submacular surgery as an alternative treatment plan.
authors.affiliation: Retina Foundation, Ahmedabad, India. drmanishnagpal@yahoo.com
authors.forename: Manish
authors.initials: M
authors.lastname: Nagpal
authors.forename: Kamal
authors.initials: K
authors.lastname: Nagpal
authors.forename: Vikram
authors.initials: V
authors.lastname: Mehta
mesh_terms: D000328:Adult; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D020256:Choroidal Neovascularization / Q000175:diagnosis / Q000601:surgery*; D006801:Humans; D008297:Male; D008566:Membranes / Q000473:pathology / Q000601:surgery; D008875:Middle Aged; D013508:Ophthalmologic Surgical Procedures; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab